Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

[Image: see text] Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competiti...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Deng, Xianming, Okram, Barun, Ding, Qiang, Zhang, Jianming, Choi, Yongmun, Adrián, Francisco J., Wojciechowski, Amy, Zhang, Guobao, Che, Jianwei, Bursulaya, Badry, Cowan-Jacob, Sandra W., Rummel, Gabriele, Sim, Taebo, Gray, Nathanael S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Chemical Society 2010
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2951064/
https://ncbi.nlm.nih.gov/pubmed/20828158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm100555f
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg